ERBB2 and breast carcinoma: Furthermore, phase III SOLAR-1 (Clinical Studies of Alpelisib in Breast Cancer 1) evaluates the safety and efficacy of alpelisib and α-specific class-1 PI3K inhibitor plus fulvestrant in HR+HER2− metastatic breast cancer patients exposed to endocrine therapy.